Abstract | OBJECTIVE: PATIENTS AND METHODS: The present study enrolled 148 patients that received either standard care, treatment with IFN alfa-2b, or IFN alfa-2b combined with lopinavir plus ritonavir. Viral testing was performed using Reverse-Transcription Polymerase Chain Reaction (RT-PCR). RESULTS: There was no significant difference in the viral-clearance time at 28 days after treatment between patients receiving standard care and those receiving anti-viral treatments. However, the average viral-clearance time of patients receiving standard care (14 days) was shorter than that for patients receiving IFN alfa-2b or IFN alfa-2b combined with lopinavir plus ritonavir (15.5 or 17.5 days) (p<0.05). Patients treated with IFN alfa-2b within five days or IFN alfa-2b combined with lopinavir plus ritonavir after three days of symptoms exhibited shorter viral-clearance times than the other groups (p<0.05). Moreover, viral-clearance times were significantly longer in patients receiving standard care or anti-viral treatment 5 days after symptoms appeared than those of patients who received these treatments within five days of symptom onset (p<0.05). CONCLUSIONS: Early symptomatic treatment is most critical for maximizing amelioration of COVID-19 infection. Anti-viral treatment might have complicated effect on viral-clearance.
|
Authors | J-Y Liu, M-X Hua, C-J Du, L Pu, P Xiang, C-S Li, H-F Xiong, X-Z Liu, Z-H Chen, W Xie, A Li |
Journal | European review for medical and pharmacological sciences
(Eur Rev Med Pharmacol Sci)
Vol. 24
Issue 22
Pg. 11939-11944
(11 2020)
ISSN: 2284-0729 [Electronic] Italy |
PMID | 33275267
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Published Erratum)
|
Chemical References |
- Antiviral Agents
- Drug Combinations
- Interferon alpha-2
- lopinavir-ritonavir drug combination
- Lopinavir
- Ritonavir
|
Topics |
- Adult
- Aged
- Antiviral Agents
(therapeutic use)
- COVID-19
(diagnosis)
- COVID-19 Nucleic Acid Testing
- Cohort Studies
- Drug Combinations
- Drug Therapy, Combination
- Early Medical Intervention
- Female
- Humans
- Interferon alpha-2
(therapeutic use)
- Lopinavir
(therapeutic use)
- Male
- Middle Aged
- Ritonavir
(therapeutic use)
- Time Factors
- Treatment Outcome
- COVID-19 Drug Treatment
|